A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

Clinical Endocrinology

Volumn 77, Issue 4, 2012, Pages 635-637

  Thondam, S K ^a   Cuthbertson, D J ^a   Aditya, B S ^a   MacFarlane, I A ^a   Wilding, J P ^a   Daousi, C ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BINGE EATING DISORDER; CASE REPORT; CHILD; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPOTHALAMIC OBESITY; INSULIN TREATMENT; LETTER; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PRIORITY JOURNAL; SCHOOL CHILD; SLEEP DISORDERED BREATHING; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; OBESITY; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 84867304980     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04368.x     Document Type: Letter

References (7)

1. Daousi, C., Dunn, A.J., Foy, P.M. et al. (2005) Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. American Journal of Medicine, 118, 45-50.
2. Daousi, C., MacFarlane, I.A., English, P.J. et al. (2005) Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage? Journal of Clinical Endocrinology and Metabolism, 90, 5025-5030.
3. Ratner, R.E., Maggs, D., Nielsen, L.L. et al. (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 8, 419-428.
4. Buse, J.B., Klonoff, D.C., Nielsen, L.L. et al. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics, 29, 139-153.
5. Gutzwiller, J.P., Göke, B., Drewe, J. et al. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut, 44, 81-86.
6. Alvarez, E., Martínez, M.D., Roncero, I. et al. (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. Journal of Neurochemistry, 92, 798-806.
7. Pannacciulli, N., Le, D.S.N.T., Salbe, A.D. et al. (2007) Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. NeuroImage, 35, 511-517.